STOCK TITAN

BioAtla (BCAB) S-1 Filings

BCAB OTC

Here are the S-1 registration statements from BioAtla Inc (BCAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-1 covers the registration statement a company files to sell shares publicly, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.

Rhea-AI Summary

BioAtla, Inc. (BCAB) registered for resale up to 8,182,110 shares of common stock by YA II PN, Ltd. (Yorkville), comprising up to 8,000,000 Advance Shares BioAtla may elect to issue and sell under its Standby Equity Purchase Agreement (SEPA) and 182,110 shares issuable upon exercise of commitment fee warrants. BioAtla receives no proceeds from Yorkville’s resales, but may receive up to $40,000,000 in aggregate gross proceeds from Advance Shares it elects to sell during the SEPA’s 36-month term, subject to the agreement’s conditions.

As of June 30, 2026, BioAtla reported approximately $1.5 million in cash and cash equivalents, which it said was insufficient to fund operations for at least 12 months from issuance of its interim financial statements, raising substantial doubt about its ability to continue as a going concern. BioAtla paused further enrollment in its Phase 1 BA3182 study while continuing treatment and patient follow-up as it re-evaluates clinical timelines amid its strategic-options process.